Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders

    January 2011 in “ Current Pharmaceutical Design
    S Paba, Roberto Frau, Sean C. Godar, Paola Devoto, Francesco Marrosu, Marco Bortolato
    Image of study
    TLDR S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.
    The document from 2011 explores the potential of steroid 5α-reductase (S5αR) inhibitors, such as finasteride and dutasteride, in treating neuropsychiatric disorders like schizophrenia, Tourette syndrome, and impulse control disorders. These inhibitors are already used for benign prostatic hyperplasia and male-pattern hair loss, with finasteride having limited side effects. Preliminary data suggest that S5αR inhibitors could be effective in conditions with dopaminergic hyperreactivity. The paper reviews evidence supporting the role of S5αR in mental disorders and its influence on neurotransmission and behavior. It also discusses the enzyme's role in steroidogenesis and its distribution in the brain. However, the effectiveness of S5αR inhibitors in neuropsychiatric disorders is not conclusive and requires further research.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 502 results

      community Detailed 6 months update for FUE HT and 4 years of FIN-MIN journey

      in Progress Pictures  194 upvotes 1 year ago
      A 25-year-old who has been using minoxidil and finasteride for 4 years to treat hair loss, underwent a successful FUE hair transplant in Mumbai, India, in April 2023. The user reported positive results, including increased hair density and reduced frizziness, and plans to continue treatment for further growth.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 3 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    5 / 5 results